Market Chameleon (Mon, 26-Jan 4:03 AM ET)
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Business Wire (Mon, 26-Jan 7:00 AM ET)
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading
TipRanks (Fri, 23-Jan 7:48 AM ET)
TipRanks (Fri, 23-Jan 7:03 AM ET)
Janux Therapeutics Inks Global Oncology Collaboration With BMS
TipRanks (Thu, 22-Jan 5:27 PM ET)
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Benzinga (Thu, 22-Jan 2:02 PM ET)
TipRanks (Thu, 22-Jan 1:36 PM ET)
Market Chameleon (Thu, 22-Jan 6:21 AM ET)
Market Chameleon (Thu, 22-Jan 2:35 AM ET)
Bristol Myers inks licensing deal with Janux for cancer therapy
Seeking Alpha News (Thu, 22-Jan 7:26 AM ET)
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Janux Therapeutics trades on the NASDAQ stock market under the symbol JANX.
As of January 27, 2026, JANX stock price climbed to $14.70 with 355,385 million shares trading.
JANX has a beta of 1.19, meaning it tends to be more sensitive to market movements. JANX has a correlation of 0.05 to the broad based SPY ETF.
JANX has a market cap of $883.38 million. This is considered a Small Cap stock.
Last quarter Janux Therapeutics reported $10 million in Revenue and -$.39 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.22.
In the last 3 years, JANX traded as high as $71.71 and as low as $5.65.
The top ETF exchange traded funds that JANX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
JANX has underperformed the market in the last year with a return of -66.7%, while the SPY ETF gained +15.6%. In the last 3 month period, JANX fell short of the market, returning -41.0%, while SPY returned +3.0%. However, in the most recent 2 weeks JANX has outperformed the stock market by returning +4.8%, while SPY returned +0.1%.
JANX support price is $14.17 and resistance is $15.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JANX shares will trade within this expected range on the day.
